PharVision Advisers’s Bunge Global BG Stock Holding History

PharVision Advisers’s Portfolio BG Stock Details BG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,276	Closed	-$255K	–	294
2024 Q4	$255K	Buy	+3,276	New	+$288K	0.22%	216

Other funds holding BG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

PharVision Advisers's BG Position: Q1 2025 in Review

PharVision Advisers sold out of Bunge Global (BG) in Q1 2025, closing a stake of 3,276 shares — an estimated $255K sold.

PharVision Advisers first reported a position in BG in Q4 2024 and held it in 1 quarter. The position peaked at $255K in Q4 2024. 588 funds tracked by Wall St. Rank hold BG as of Q1 2025.

PharVision Advisers reported no remaining Bunge Global position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 3,276 Bunge Global shares in Q1 2025, an estimated $255K.
PharVision Advisers first reported a position in Bunge Global in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Bunge Global position peaked at $255K in Q4 2024.
588 funds tracked by Wall St. Rank held Bunge Global as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.